IMD2032 / Affinity Biopharma - LARVOL DELTA

Novel tumor microenvironment (TME) activated interleukin-2 (IL-2) fused to anti-PD-1 or anti-PD-1/VEGF-A antibodies for enhanced anti-tumor immunity (AACR 2026) - "Preclinical toxicology studies in cynomolgus monkeys indicated that IMD2035 was well tolerated following repeated doses of 12 mg/kg, exceeding the clinical exposure levels of anti-PD1-VEGF antibodies. Collectively, these findings support the favorable safety profile and therapeutic efficacy of IMD-101, IMD-2032, and IMD-2035, highlighting their potential as next-generation immunotherapeutic candidates for clinical development."

Biomarker • Tumor microenvironment • Oncology • FCGR3A • IL2 • LGMN • PD-L1